DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on June 7, 2006; DOI: 10.1124/dmd.106.010009


0090-9556/06/3409-1495-1501$20.00
DMD 34:1495-1501, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.010009v1
34/9/1495    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujimoto, K.
Right arrow Articles by Yamoto, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujimoto, K.
Right arrow Articles by Yamoto, T.

Characterization of Phenotypes in Gstm1-null Mice by Cytosolic and in Vivo Metabolic Studies Using 1,2-Dichloro-4-Nitrobenzene

Kazunori Fujimoto, Shingo Arakawa, Yukari Shibaya, Hiroaki Miida, Yosuke Ando, Hiroaki Yasumo, Ayako Hara, Minoru Uchiyama, Haruo Iwabuchi, Wataru Takasaki, Sunao Manabe, and Takashi Yamoto

Medicinal Safety Research Laboratories, Sankyo Co., Ltd., Shizuoka, Japan (K.F., S.A., Y.S., H.M., Y.A., W.T., S.M., T.Y.); and Biomedical Research Laboratories (H.Y., A.H.) and Drug Metabolism and Pharmacokinetics Research Laboratories (M.U., H.I.), Sankyo Co., Ltd., Tokyo, Japan

Glutathione S-transferase Mu 1 (GSTM1) has been regarded as one of the key enzymes involved in phase II reactions in the liver, because of its high expression level. In this study, we generated mice with disrupted glutathione S-transferase Mu 1 gene (Gstm1-null mice) by gene targeting, and characterized the phenotypes by cytosolic and in vivo studies. The resulting Gstm1-null mice appeared to be normal and were fertile. Expression analyses for the Gstm1-null mice revealed a deletion of Gstm1 mRNA and a small decrease in glutathione S-transferase alpha 3 mRNA. In the enzymatic study, GST activities toward 1,2-dichloro-4-nitrobenzene (DCNB) and 1-chloro-2,4-dinitrobenzene (CDNB) in the liver and kidney cytosols were markedly lower in Gstm1-null mice than in the wild-type control. Gstm1-null mice had GST activities of only 6.1 to 21.0% of the wild-type control to DCNB and 26.0 to 78.6% of the wild-type control to CDNB. After a single oral administration of DCNB to Gstm1-null mice, the plasma concentration of DCNB showed larger AUC0–24 (5.1–5.3 times, versus the wild-type control) and higher Cmax (2.1–2.2 times, versus the wild-type control), with a correspondingly lower level of glutathione-related metabolite (AUC0–24, 9.4–17.9%; and Cmax, 9.7–15.6% of the wild-type control). In conclusion, Gstm1-null mice showed markedly low ability for glutathione conjugation to DCNB in the cytosol and in vivo and would be useful as a deficient model of GSTM1 for absorption, distribution, metabolism, and excretion/toxicology studies.


Address correspondence to: Kazunori Fujimoto, Medicinal Safety Research Laboratories, Sankyo Co., Ltd., 717 Horikoshi, Fukuroi, Shizuoka 437-0065, Japan. E-mail: kazunf{at}sankyo.co.jp




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
K. Fujimoto, S. Arakawa, T. Watanabe, H. Yasumo, Y. Ando, W. Takasaki, S. Manabe, T. Yamoto, and S.-i. Oda
Generation and Functional Characterization of Mice with a Disrupted Glutathione S-Transferase, Theta 1 Gene
Drug Metab. Dispos., December 1, 2007; 35(12): 2196 - 2202.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.